Skye Bioscience, Inc. · NASDAQ:SKYE
Skye Bioscience — Investor Presentation (July 2021)
22 slides from Skye Bioscience's investor presentation, July 2021
Slide 1: Unlocking the Pharmaceutical Potential of Cannabinoids
Unlocking the Pharmaceutical Potential of Cannabinoids Corporate Presentation July 2021 • OTCQB: SKYE
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation contains “forward-looking statements”, including All information contained in this presentation is provided as of the date statements regarding Skye Bioscience, Inc. and its subsidiaries, within of the presentation and is subject to change without notice. Neither t
Slide 3: Overview
Overview Biopharmaceutical company developing differentiated, synthetic, proprietary NOVEL TECHNOLOGY cannabinoid derivatives to treat diseases Bioengineered, synthetic cannabinoid derivatives designed to with significant unmet medical needs significantly enhance therapeutic benefits COMMERCIAL OPPO
Slide 4: Glaucoma is the leading cause of irreversible blindness
Glaucoma is the leading cause of irreversible blindness Glaucoma is a disease that leads to the progressive damage of retinal ganglion cells, which make up the optic nerve, and without intervention will gradually lead to irreversible blindness Healthy Vision Early Glaucoma Advanced Glaucoma skyebios
Slide 5: Large & growing patient population
Large & growing patient population 78M 100M Current Glaucoma Patients 2040 Predicted Glaucoma Patients $6.6B current global market and expected to reach $11B by 2027 with a growing aging population (CAGR 6.6%) skyebioscience.com • 5
Slide 6: How does glaucoma cause blindness?
How does glaucoma cause blindness? A common trait of glaucoma involves increased pressure in the eye - intraocular pressure (IOP) HEALTHY GLAUCOMA Production/drainage of Drainage canal becomes blocked, Increased pressure damages aqueous humor (fluid) fluid builds up and leads to optic nerve cells, r
Slide 7: Current therapies leave notable unmet needs
Current therapies leave notable unmet needs IOP Class of Medication Generic Example MOA Potential Side Effects Reduction irritation, redness, blurred vision, dry eyes, • Current drugs aim to lower IOP in order to Prostaglandins Latanoprost 30-35% ↑ Outflow light sensitivity, headaches, eyelash chang
Slide 8: Relevance of THC to glaucoma
Relevance of THC to glaucoma • Cannabinoid receptors throughout the body play an important role in managing many vital body functions • Eye is rich with cannabinoid receptors, specifically in tissues involved in managing fluid production and drainage as well as cells responsible for vision • THC and
Slide 9: Multiple independent studies have demonstrated THC's ability to lower IOP
Multiple independent studies have demonstrated THC’s ability to lower IOP Y. Panahi et al. / Biomedicine & Pharmacotherapy 86 (2017) 620–627 skyebioscience.com • 9
Slide 10: Challenges to THC as an effective treatment of glaucoma
Challenges to THC as an effective treatment of glaucoma Systemic Delivery Local Delivery • Requires relatively high dose to achieve • THC is lipophilic - challenging to deliver into therapeutic effect in the eye and penetrate aqueous tissue, like the eye • Variable pharmacokinetics and • Oil and wat
Slide 11: SKYE's approach unlocks therapeutic value of THC
SKYE’s approach unlocks therapeutic value of THC • Rational drug design and bioengineering used to •Inside the eye, THCVHS is converted back into THC by develop a synthetic prodrug of THC, called THCVHS enzymes that cleave VHS arm of the molecule • Valine-hemi-succinate amide ester (VHS) addition •T
Slide 12: THCVHS lowers IOP better than both market leaders
THCVHS lowers IOP better than both market leaders In a preclinical model using New Zealand white rabbits: • THCVHS demonstrates superior decline in IOP versus latanoprost and timolol • THCVHS demonstrates superior duration of response Average IOP vs Time profile of Latanoprost (0.005%) vs THCVHS (1.
Slide 13: THCVHS can be combined to enhance effects
THCVHS can be combined to enhance effects In a preclinical model using Dutch Belted pigmented rabbits: • THCVHS alone demonstrates superior IOP-lowering and duration vs lantanoprost • THCVHS with netarsudil further enhances IOP-lowering and duration of effect Average IOP vs Time profile of Latanopro
Slide 14: Multi-factorial mechanism of action
Multi-factorial mechanism of action • In an ex vivo model of human trabecular meshwork, the tissues responsible for fluid drainage, THC significantly lowered pressure and increased drainage in both healthy and diseased tissue • THC treatment also significantly reduced markers of fibrosis and inflamm
Slide 15: Not all glaucoma patients have elevated IOP
Not all glaucoma patients have elevated IOP • Large proportion of glaucoma patients present % of glaucoma patients with normal IOP with normal IOP, but still suffer progressive damage to optic nerve cells and vision loss • Not clear what causes neurodegeneration of optic nerve in these patients • A
Slide 16: Cannabinoids demonstrate neuroprotection
Cannabinoids demonstrate neuroprotection • Multiple studies, in different animal species & models, of glaucoma have demonstrated ability of cannabinoids to promote health and survival of optic nerve cells • Optic nerve injury model in rats planned to initiate in Q2-21 to validate neuroprotection pro
Slide 17: Positioned for value creation
Positioned for value creation First human trial will be fast, low cost, and include assessment of intraocular pressure H1 2021 H2 2021 H1 2022 ü Initiate preclinical studies for § Complete GMP manufacturing of § Phase 1 data for THCVHS CBDVHS THCVHS § FDA pre-IND meeting for THCVHS ü Preclinical com
Slide 18: Capitalization
Capitalization 1 1 2 372.0 M 95.9 M 5.1 M Common Shares Outstanding Options & Warrants Convertible Debt Shares (Converted Basis) 1 3 473.0 M 59.5 M San Diego, CA Base of Operations Fully Diluted Market Cap 1 Based on 10Q filed 21/05/07 2 Based on principal balance and accrued interest outstanding as
Slide 19: Management: Focused on delivering near-term data outcomes
Management: Focused on delivering near-term data outcomes Punit Dhillon Richard Janney Tu Diep, MSc Chief Executive Officer Principal Accounting Officer Sr Vice President, Development • 30 years of business experience and served as a • Senior leaderships positions at Element • Co-founded and led Onc
Slide 20: Board Directors & Advisors Offer Expert Guidance
Board Directors & Advisors Offer Expert Guidance Eminent experts in cannabinoid science, ophthalmology, research, and development Board of Director Clinical Advisors Scientific Advisors Punit Dhillon Robert Ritch, MD Giovanni Appendino, PhD Chair Professor of Ophthalmology, Mt. Sinai Professor of Or
Slide 21: Unique competitive position
Unique competitive position Demonstrated greater IOP lowering than market-leading glaucoma therapeutics Potential neuroprotection capabilities would be a game changer Key preclinical data (IOP/neuroprotection) in Q2-21 First clinical trial: fast; low-cost; will include assessment of intraocular pres
Slide 22: To learn more please contact
To learn more please contact: Karam Takhar VP, Corporate Development & Investor Relations [email protected] 1 (858) 410-0266